Efficacy and effectiveness of live attenuated influenza vaccine in school-age children

Kathleen Coelingh*, Ifedapo Rosemary Olajide, Peter MacDonald, Ram Yogev

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Evidence of high efficacy of live attenuated influenza vaccine (LAIV) from randomized controlled trials is strong for children 2-6 years of age, but fewer data exist for older school-age children. We reviewed the published data on efficacy and effectiveness of LAIV in children ≥5 years. QUOSA (Elsevier database) was searched for articles published from January 1990 to June 2014 that included FluMist, LAIV, CAIV, cold adapted influenza vaccine, live attenuated influenza vaccine, live attenuated cold adapted or flu mist. Studies evaluated included randomized controlled trials, effectiveness and indirect protection studies. This review demonstrates that LAIV has considerable efficacy and effectiveness in school-age children.

Original languageEnglish (US)
Pages (from-to)1331-1346
Number of pages16
JournalExpert Review of Vaccines
Issue number10
StatePublished - Oct 3 2015


  • effectiveness
  • efficacy
  • influenza vaccine
  • live attenuated influenza vaccine
  • school-age children

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Pharmacology
  • Immunology


Dive into the research topics of 'Efficacy and effectiveness of live attenuated influenza vaccine in school-age children'. Together they form a unique fingerprint.

Cite this